DSB 2455
Alternative Names: DSB-2455Latest Information Update: 02 Apr 2026
At a glance
- Originator Duke Street Bio
- Class Antineoplastics; Small molecules
- Mechanism of Action Poly(ADP-ribose) polymerase-1 inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 30 Oct 2024 Phase-I clinical trials in Solid tumours (Second-line therapy or greater, Late-stage disease, Metastatic disease) in Spain (PO) (NCT06458712)
- 23 Oct 2024 Safety, pharmacokinetics and pharmacodynamics data from a preclinical trial in Solid tumours presented at the 36th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics (EORTC-NCI-AACR-2024)
- 14 Jun 2024 Duke Street Bio plans a phase I trial for Solid tumours (Monotherapy, Combination-therapy, Late-stage disease, Second-line therapy or grater, Metastatic disease) (PO), in September 2024 (NCT06458712)